Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an update.
Shandong Xinhua Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, has received a Drug Registration Certificate for its Ursodeoxycholic Acid Capsules from the National Medical Products Administration. This approval marks a significant step for the company in expanding its product offerings and strengthening its position in the pharmaceutical market, potentially impacting its operations and stakeholders positively.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited operates in the pharmaceutical industry, focusing on the production and distribution of various pharmaceutical products. The company is known for its development of prescription drugs, with a market focus on both domestic and international markets.
Average Trading Volume: 8,154,323
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.64B
Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.